NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Buy VYGR with Qtrade Free VYGR Stock Alerts $8.23 +0.13 (+1.60%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$8.05▼$8.3050-Day Range$7.42▼$10.5452-Week Range$6.06▼$14.07Volume296,356 shsAverage Volume478,409 shsMarket Capitalization$447.63 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Voyager Therapeutics alerts: Email Address Voyager Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside118.7% Upside$18.00 Price TargetShort InterestBearish7.74% of Shares Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment1.29Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.39) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.83 out of 5 starsMedical Sector214th out of 923 stocksBiological Products, Except Diagnostic Industry25th out of 154 stocks 4.4 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVoyager Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Voyager Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.74% of the outstanding shares of Voyager Therapeutics have been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 21.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.97. Previous Next 2.4 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Voyager Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -96% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to decrease in the coming year, from ($1.39) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is -164.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is -164.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Voyager Therapeutics Stock (NASDAQ:VYGR)Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More VYGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesMay 20, 2024 | americanbankingnews.comVoyager Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.31) Per Share (NASDAQ:VYGR)May 18, 2024 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Rating Reiterated by HC WainwrightMay 17, 2024 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Rating Reiterated by OppenheimerMay 16, 2024 | finance.yahoo.comVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s DiseaseMay 16, 2024 | globenewswire.comVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's DiseaseMay 16, 2024 | americanbankingnews.comVoyager Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.46) Per Share, Wedbush Forecasts (NASDAQ:VYGR)May 15, 2024 | benzinga.comLatest News for Voyager Therapeutics Stock (NASDAQ:VYGR)May 14, 2024 | finanznachrichten.deVoyager Therapeutics, Inc.: Voyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsMay 14, 2024 | markets.businessinsider.comPositive Outlook for Voyager Therapeutics: Buy Rating Affirmed Amid Pipeline Progress and Strong Financial PositionMay 14, 2024 | msn.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comQ1 2024 Voyager Therapeutics Inc Earnings CallMay 14, 2024 | finance.yahoo.comVoyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | sfgate.comVoyager Therapeutics: Q1 Earnings SnapshotMay 13, 2024 | msn.comVoyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02MMay 13, 2024 | globenewswire.comVoyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsMay 10, 2024 | msn.comVoyager 1 was in crisis in interstellar space. NASA wouldn’t give up.May 8, 2024 | msn.comThe Invincible - Official Voyager Update TrailerMay 8, 2024 | msn.com8 Coolest Starships in Star Trek: VoyagerMay 8, 2024 | finance.yahoo.comVoyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingMay 6, 2024 | finance.yahoo.comVoyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returnsMay 6, 2024 | globenewswire.comVoyager Therapeutics Announces First Quarter 2024 Conference Call and WebcastApril 30, 2024 | msn.comScientist Warns That NASA’s Voyager Probes Are “Dodging Bullets Out There”April 29, 2024 | msn.com7 Star Trek: Voyager Alien Villains Worse Than Discoverys BreenApril 27, 2024 | msn.comSilent no more: NASA hears from Voyager 1, the most distant spacecraftApril 26, 2024 | yahoo.comInside NASA's 5-month fight to save the Voyager 1 mission in interstellar spaceSee More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees162Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$30.00 Low Stock Price Target$8.00 Potential Upside/Downside+118.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins-2.56% Pretax Margin-1.95% Return on Equity-1.28% Return on Assets-0.85% Debt Debt-to-Equity RatioN/A Current Ratio5.64 Quick Ratio5.64 Sales & Book Value Annual Sales$250.01 million Price / Sales1.79 Cash Flow$3.03 per share Price / Cash Flow2.72 Book Value$6.27 per share Price / Book1.31Miscellaneous Outstanding Shares54,390,000Free Float51,837,000Market Cap$447.63 million OptionableOptionable Beta0.98 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 66)M.D., Ph.D., President, CEO & Director Comp: $1.01MMs. Robin Swartz (Age 53)COO, Principal Financial & Accounting Officer and Acting Chief Business Officer Comp: $661.98kMs. Jacquelyn Fahey Sandell Esq. (Age 53)J.D., Chief Legal Officer Comp: $538.16kDr. Krystof Bankiewicz M.D.Ph.D., FounderDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 65)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMr. Todd Carter Ph.D. (Age 54)Chief Scientific Officer Ms. Michelle Quinn SmithChief Human Resources OfficerDr. Maria Lopez-Bresnahan M.B.A.M.D., Senior Vice President of Translational Medicine & Clinical DevelopmentMore ExecutivesKey CompetitorsAllogene TherapeuticsNASDAQ:ALLOEditas MedicineNASDAQ:EDITOcugenNASDAQ:OCGNTScan TherapeuticsNASDAQ:TCRXLexeo TherapeuticsNASDAQ:LXEOView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 1,000,000 shares on 5/24/2024Ownership: 4.214%Ikarian Capital LLCSold 125,000 shares on 5/17/2024Ownership: 0.333%Plato Investment Management LtdBought 4,119 shares on 5/17/2024Ownership: 0.008%Virtus Investment Advisers Inc.Bought 12,648 shares on 5/16/2024Ownership: 0.023%California State Teachers Retirement SystemSold 1,271 shares on 5/16/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions VYGR Stock Analysis - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued twelve-month price objectives for Voyager Therapeutics' shares. Their VYGR share price targets range from $8.00 to $30.00. On average, they expect the company's share price to reach $18.00 in the next year. This suggests a possible upside of 118.7% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2024? Voyager Therapeutics' stock was trading at $8.44 at the beginning of the year. Since then, VYGR stock has decreased by 2.5% and is now trading at $8.23. View the best growth stocks for 2024 here. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its earnings results on Wednesday, February, 28th. The company reported $1.25 EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The business earned $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 1.28% and a negative net margin of 2.56%. What ETFs hold Voyager Therapeutics' stock? ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include Franklin Genomic Advancements ETF (HELX).iShares Neuroscience and Healthcare ETF (IBRN). What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.94%), Farallon Capital Management LLC (4.21%), Price T Rowe Associates Inc. MD (1.92%), Acadian Asset Management LLC (0.85%), Ikarian Capital LLC (0.33%) and ClariVest Asset Management LLC (0.18%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYGR) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWARNING about the death of the U.S. dollar…Colonial Metals$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBiden replacement revealed?Paradigm PressNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTradeThe only AI company to buyPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.